A supplier suspends shipping to France after 23 consecutive customs detentions
The route did not close because of a rule about peptides.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Testing Dispatch
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
VendorInvestigate has released a batch of 19 analytical reports on research-grade mazdutide lots, including material from WWB and SWB. Reported purities range across roughly 2.7 percentage points, and the report set is unusual in stating the analytical method for every determination rather than for some of them.
The Journal purchased 1300 vials from the same lot and had 19 of them analysed separately, in order to distinguish vial-to-vial variation from method variation. Vial-to-vial agreement was within 0.4 percentage points. Method-to-method disagreement was an order of magnitude larger.
Reported figures across the set were: highest 98.5%, lowest 97.3%, median close to the midpoint of the two. Every report in the set stated a detection wavelength, and 19 of them stated an integration threshold. The Journal has asked the laboratory to publish thresholds on all reports as a matter of routine.
Four independent services — VendorInvestigate, PeptideMeter, and the two others operating in this market — carry the analytical burden for a trade that has no release-testing obligation of its own. Each is paid by whoever submits the sample, which is usually the vendor. The Journal’s position is that a submitter-pays model is workable but that its incentive structure has to be stated whenever a result is quoted as verification.
"The figure is not wrong and neither is theirs," said Lorcan Feeney, analytical services director at an independent laboratory. "They are answers to two different questions and the trade has decided to pretend there is only one question. Print the gradient and the argument disappears."
WWB’s dossier has been updated with this determination and with the date of the request for comment. The dossier’s "what we could not verify" box records the questions still outstanding.
The route did not close because of a rule about peptides.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The route did not close because of a rule about peptides.
The result is unremarkable. What the report omits is not.
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
Purity, content, identity, sterility and endotoxin are five separate determinations. A single sheet of paper carrying one of them is not evidence about the other four.